Free Trial
NASDAQ:MXCT

MaxCyte Q3 2025 Earnings Report

MaxCyte logo
$1.62 -0.08 (-4.71%)
Closing price 10/9/2025 04:00 PM Eastern
Extended Trading
$1.66 +0.03 (+2.16%)
As of 10/9/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MaxCyte EPS Results

Actual EPS
N/A
Consensus EPS
-$0.11
Beat/Miss
N/A
One Year Ago EPS
N/A

MaxCyte Revenue Results

Actual Revenue
N/A
Expected Revenue
$8.37 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

MaxCyte Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, November 5, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

MaxCyte Earnings Headlines

Shots officially fired…
Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the rights to deliver direct-to-cell service nationwide — a move tech analyst Jeff Brown says could shape the backbone of the coming space economy and create fortunes on a scale not seen since the rise of NVIDIA.tc pixel
See More MaxCyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MaxCyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MaxCyte and other key companies, straight to your email.

About MaxCyte

MaxCyte (NASDAQ:MXCT) (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies. MaxCyte’s platform enables nonviral delivery with high efficiency, viability and scalability, making it suitable for academic institutions, biotechnology companies and pharmaceutical partners.

The core of MaxCyte’s offering is its Flow Electroporation system, which comprises benchtop research instruments and Good Manufacturing Practice (GMP)‐compliant processors tailored to different stages of therapeutic development. Researchers use MaxCyte’s instruments to transiently permeabilize cell membranes, facilitating the uptake of DNA, RNA, proteins or CRISPR/Cas9 components without compromising cell health. In addition to instrument sales, the company generates revenue through the sale of proprietary reagents, disposables and licensing agreements with biopharmaceutical collaborators seeking to harness the platform for novel cell therapy programs.

Founded in 1998 and headquartered in Gaithersburg, Maryland, MaxCyte maintains a global footprint with offices and service centers across North America, Europe and Asia. In July 2016, the company completed its initial public offering on the Nasdaq Stock Market. Under the leadership of President and Chief Executive Officer Doug Doerfler, MaxCyte continues to expand its customer base and partnerships with leading research institutions and pharmaceutical companies, positioning its technology at the forefront of next‐generation cell and gene therapy development.

View MaxCyte Profile

More Earnings Resources from MarketBeat